New features in MEK retinopathy
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The use of molecularly targeted therapy is becoming widespread in oncology. These agents cause tumour-specific genetic alterations in signal transduction pathways, hence less generalised toxicity. Dabrafenib, a BRAF inhibitor and Trametinib, a MEK inhibitor are two molecularly targeted agents recently approved for treatment of advanced, unresectable melanomas. MEK retinopathy is a recently introduced term describing retinal toxicity secondary to MEK inhibitors. CASE PRESENTATION: A 71-year-old man presented with 'circular, green patches' in his central vision for 2 weeks. He had multiple relapsed stage IV BRAF gene mutant malignant melanoma. He was on treatment with Dabrafenib (Tafinlar) for 7 months and Trametinib (Mekinist) for 4 months respectively. The fundus looked normal. The OCT scan showed bilateral symmetrical cystoid macular edema, intraretinal and subretinal fluid, thickening of elliposoid zone and subretinal granular deposits. The symptoms resolved with temporary cessation of chemotherapy but OCT signs persisted. CONCLUSION: This case report identifies two new remarkable features of MEK retinopathy as thickening of ellipsoid zone and 'starry sky' pattern of distribution of subretinal granular deposits. These changes signify photoreceptors/ RPE toxicity and dysfunction. The subretinal granular deposits showed increased autofluorescence suggested abnormal lipofuscin clearance due to RPE dysfunction. The molecularly targeted therapy has revolutionized the cancer treatment and increased the survival rate. These agents are relatively new and recently approved for clinical use and most of them are associated with ocular toxicities. Awareness of ocular symptoms, side-effect profile of drugs, monitoring regime and liaison between oncologist and eye care professional with ocular imaging is key to early diagnosis and management of ocular adverse events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Other reported features of MEKAR include the thickening of the ellipsoid zone and a “starry sky” pattern of distribution of subretinal granular deposits, with suspected photoreceptor/ RPE toxicity and dysfunction [ 221 ]”
From MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges (2023) · cites this paper as [221]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Long, G. V., Menzies, A. M., Nagrial, A. M., Haydu, L. E., Hamilton, A. L., Mann, G. J., Hughes, T. M., Thompson, J. F., Scolyer, R. A., & Kefford, R. F. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.4327 · Cited by 1,042
Dabrafenib and Trametinib, Alone and in Combination for BRAF-Mutant Metastatic Melanoma
Menzies, A. M., & Long, G. V. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2054 · Cited by 170
Transient MEK inhibitor-associated retinopathy in metastatic melanoma
Urner-Bloch, U., Urner, M., Stieger, P., Galliker, N., Winterton, N., Zubel, A., Parseval, L. M., Dummer, R., & Goldinger, S. M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu169 · Cited by 135
Ocular toxicities of MEK inhibitors and other targeted therapies
Stjepanovic, N., Velazquez-Martin, J. P., & Bedard, P. L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw100 · Cited by 110
Effect of inhibition of the FGFR–MAPK signaling pathway on the development of ocular toxicities
van der Noll, R., Leijen, S., Neuteboom, G. H. G., Beijnen, J. H., & Schellens, J. H. M. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.01.003 · Cited by 107
Huang, W., Yang, A. H., Matsumoto, D., Collette, W., Marroquin, L., Ko, M., Aguirre, S., & Younis, H. S. (2009) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2009.0060 · Cited by 90
MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity
Duncan, K. E., Chang, L. Y., & Patronas, M. (2015) · Eye · doi:10.1038/eye.2015.82 · Cited by 87
Subretinal Fluid Associated with MEK Inhibitor Use in the Treatment of Systemic Cancer
Weber, M. L., Liang, M. C., Flaherty, K. T., & Heier, J. S. (2016) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.0090 · Cited by 86
MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects
Urner-Bloch, U., Urner, M., Jaberg-Bentele, N., Frauchiger, A. L., Dummer, R., & Goldinger, S. M. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.018 · Cited by 82
Cited by
Targeted drug delivery strategies for precision medicines
Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-020-00269-6 · Cited by 1,183
MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges
Moustardas, P., Aberdam, D., & Lagali, N. (2023) · Cells · doi:10.3390/cells12040617 · Cited by 63
“Other reported features of MEKAR include the thickening of the ellipsoid zone and a “starry sky” pattern of distribution of subretinal granular deposits, with suspected photoreceptor/ RPE toxicity and dysfunction [221].”
BackgroundFauviaux, E., Promelle, V., Boucenna, V., Jany, B., Errera, M. H., Delbarre, M., & Boucenna, W. (2022) · Journal Français d'Ophtalmologie · doi:10.1016/j.jfo.2021.08.005 · Cited by 8
Metadata
- Authors
- Tyagi, P., & Santiago, C.
- Affiliations
- Aberdeen Royal Infirmary (GB)
- Corresponding author
- Tyagi, Pallavi
- Venue
- BMC Ophthalmology
- Published
- 2018-09
- Volume
- 18
- Issue
- S1
- Pages
- 221-221
- ISSN
- 1471-2415 (ISSN-L)
- PMC
- PMC6157024
- OpenAlex
- W2890507526
- Cited by
- 39
- References
- 17
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 5 · 2021: 7 · 2020: 9 · 2019: 3 · 2018: 1
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- BMC Ophthalmology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- trametinib, dabrafenib, BRAF inhibitors, melanoma, retinal toxicity, cystoid macular edema, retinal pigment epithelium dysfunction, autofluorescence, ocular adverse effects, targeted therapy
- MeSH terms
- Aged, Humans, Imidazoles, Macular Edema, Male, Oximes, Pyridones, Pyrimidinones, Retinal Diseases, Skin Neoplasms, Photoreceptor Cells, Vertebrate, Mitogen-Activated Protein Kinase Kinases, Tomography, Optical Coherence, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Retinal Pigment Epithelium, Subretinal Fluid, Molecular Targeted Therapy, Paraneoplastic Syndromes, Ocular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New features in MEK retinopathy. https://app.cochat.ai/papers/10.1186/s12886-018-0861-8
- The paper
- Tyagi, P., & Santiago, C. (2018). New features in MEK retinopathy. BMC Ophthalmology. https://doi.org/10.1186/s12886-018-0861-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.